1. Home
  2. Directory
  3. North Carolina
  4. Winston Salem
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1619952991

CHRISTOPHER ALAN OHL MD
Prescription History 1619952991
Internal Medicine - Infectious Disease in Winston Salem, NC

NPI Status: Active since December 09, 2005

Contact Information

MEDICAL CENTER BLVD
WINSTON SALEM, NC
ZIP 27157
Phone: (336) 716-2255

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CHRISTOPHER ALAN OHL MD, an active Infectious Disease specialist practicing in Winston Salem, NC. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 339 documented patient claims. Among these therapy options, the most frequently utilized medication is Arexvy, which accounts for 107 claims alone.

Medication Index

A
B
S
T
No matching medications currently found on file.

Arexvy

Generic Formulation: Rsvpref3 Antigen/As01e/PfSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 107
30-Day Fills 107.0
Days Supply 107
NC State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$319.83

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Atovaquone-Proguanil Hcl

Generic Formulation: Atovaquone/Proguanil HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 38
30-Day Fills 39.8
Days Supply 875
NC State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills39.0
Peer Average Days Supply831
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,627.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$95.46

State Avg Cost Per Claim

$102.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: atovaquone and proguanil. It is used to prevent and treat malaria caused by mosquito bites in countries where malaria is common. Malaria parasites can enter the body through these mosquito bites, and then live in body tissues such as red blood cells or the liver. This medication is used to kill the malaria parasites living inside red blood cells and other tissues. In some cases, you may need to take a different medication (such as primaquine) to complete your treatment. Both medications may be needed for a complete cure and to prevent the return of infection (relapse). Atovaquone/proguanil belongs to a class of drugs known as antimalarials. The United States Centers for Disease Control provide updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 60
30-Day Fills 60.0
Days Supply 345
NC State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills37.3
Peer Average Days Supply331
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 71.4% higher than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $647.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.79

State Avg Cost Per Claim

$11.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Boostrix Tdap

Generic Formulation: Diphth,pertuss(Acell),tet VacSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 21
NC State Average Benchmarks
Peer Average Claims101.0
Peer Average 30-Day Fills101.6
Peer Average Days Supply133
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.2% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,608.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$76.59

State Avg Cost Per Claim

$65.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Shingrix

Generic Formulation: Varicella-Zoster Ge/As01b/PfSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 93
30-Day Fills 93.0
Days Supply 93
NC State Average Benchmarks
Peer Average Claims118.0
Peer Average 30-Day Fills118.4
Peer Average Days Supply159
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,351.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$218.83

State Avg Cost Per Claim

$199.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Typhim Vi

Generic Formulation: Typhoid Vi Polysacch VaccineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 20
NC State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply53
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,451.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$222.58

State Avg Cost Per Claim

$140.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CHRISTOPHER ALAN OHL MD provides transparency into local medical care patterns within Winston Salem, NC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.